Aura Biosciences Inc (NASDAQ: AURA) has experienced a rise in its stock price by 12.19 compared to its previous closing price of 8.04. However, the company has seen a gain of 22.06% in its stock price over the last five trading days. globenewswire.com reported 2024-09-03 that Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology
Is It Worth Investing in Aura Biosciences Inc (NASDAQ: AURA) Right Now?
Company’s 36-month beta value is 0.34.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AURA is 41.76M, and currently, short sellers hold a 2.94% ratio of that floaft. The average trading volume of AURA on September 11, 2024 was 176.10K shares.
AURA’s Market Performance
AURA’s stock has seen a 22.06% increase for the week, with a 8.67% rise in the past month and a 24.59% gain in the past quarter. The volatility ratio for the week is 7.59%, and the volatility levels for the past 30 days are at 6.21% for Aura Biosciences Inc The simple moving average for the past 20 days is 15.58% for AURA’s stock, with a 12.41% simple moving average for the past 200 days.
Analysts’ Opinion of AURA
Many brokerage firms have already submitted their reports for AURA stocks, with H.C. Wainwright repeating the rating for AURA by listing it as a “Buy.” The predicted price for AURA in the upcoming period, according to H.C. Wainwright is $21 based on the research report published on July 25, 2024 of the current year 2024.
BTIG Research gave a rating of “Buy” to AURA, setting the target price at $38 in the report published on April 17th of the previous year.
AURA Trading at 8.35% from the 50-Day Moving Average
After a stumble in the market that brought AURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.96% of loss for the given period.
Volatility was left at 6.21%, however, over the last 30 days, the volatility rate increased by 7.59%, as shares surge +13.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.31% upper at present.
During the last 5 trading sessions, AURA rose by +22.06%, which changed the moving average for the period of 200-days by +12.89% in comparison to the 20-day moving average, which settled at $7.86. In addition, Aura Biosciences Inc saw 1.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AURA starting from de los Pinos Elisabet, who sale 15,853 shares at the price of $7.64 back on Jan 23 ’24. After this action, de los Pinos Elisabet now owns 161,438 shares of Aura Biosciences Inc, valued at $121,141 using the latest closing price.
Feder Julie B, the Chief Financial Officer of Aura Biosciences Inc, sale 6,609 shares at $7.64 during a trade that took place back on Jan 23 ’24, which means that Feder Julie B is holding 62,991 shares at $50,521 based on the most recent closing price.
Stock Fundamentals for AURA
Current profitability levels for the company are sitting at:
- -42.98 for the present operating margin
- 0.35 for the gross margin
The net margin for Aura Biosciences Inc stands at -39.24. The total capital return value is set at -0.43. Equity return is now at value -45.09, with -39.26 for asset returns.
Based on Aura Biosciences Inc (AURA), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -3.85. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -38.32.
Currently, EBITDA for the company is -83.7 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 212.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.54.
Conclusion
In a nutshell, Aura Biosciences Inc (AURA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
